Firm & fund profile / Sourced portfolio
U.S. Congress (via HHS/NIH appropriations)
Tracked participation in 1 Atlas company, with 5 explicitly attributed leads.
1portfolio companies
5round participations
5lead positions
$7Bled round total
Conviction
Most recent leads
The latest rounds this investor is sourced as leading, newest first.
Mar 2022ARPA-HFederal appropriations (establishment funding; FY 2022 final)$1BUndatedARPA-HFederal appropriations (FY 2023 final)$1.5BUndatedARPA-HFederal appropriations (FY 2024 final)$1.5BUndatedARPA-HFederal appropriations (FY 2025 enacted)$1.5BUndatedARPA-HFederal appropriations (FY 2026 final; operating plan)$1.5B
Capital activity
Portfolio
CompanyLatest valuationFirst → latestRoundsRoleAttributed partner
DateCompanyRoundRaisedValuationRoleEvidence
DateCompanyRoundRaisedValuationRoleEvidence